CAH vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Cardinal Health presents a dichotomy of strong growth and fragile liquidity, anchored by a stable Piotroski F-Score of 4/9. While the company exhibits impressive YoY revenue and earnings growth (~19%) and consistently beats analyst estimates, its operational health is hampered by razor-thin profit margins (0.68%) and a concerning current ratio of 0.91. The stock is trading slightly below its intrinsic value of $205.03, but bearish insider activity and a 0/100 technical trend suggest immediate headwinds despite a 'strong_buy' analyst consensus.
JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.
Compare Another Pair
Related Comparisons
CAH vs JNJ: Head-to-Head Comparison
This page compares Cardinal Health, Inc. (CAH) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.